

## WEST Search History





DATE: Monday, June 21, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L24	proteinase K and prion	32
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L23	US-6613505-B2.did.	1
		<i>DB=DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L22	chymotrypsin and prion	4
<input type="checkbox"/>	L21	SAAPPN substrate	0
<input type="checkbox"/>	L20	n-succinyl-Ala-Ala-Pro-Phe-p-NitroAnilide substrate	0
<input type="checkbox"/>	L19	casein resorufin and prion	1
		<i>DB=USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L18	casein resorufin and prion	0
<input type="checkbox"/>	L17	casein resorufin	9
<input type="checkbox"/>	L16	n-succinyl-Ala-Ala-Pro-Phe-p-NitroAnilide substrate	2
<input type="checkbox"/>	L15	SAAPPN substrate	0
<input type="checkbox"/>	L14	SAAPPN and prion	0
<input type="checkbox"/>	L13	chymotrypsin and prion.clm.	9
<input type="checkbox"/>	L12	chymotrypsin and prion	60
<input type="checkbox"/>	L11	6221614.pn.	1
<input type="checkbox"/>	L10	proteinase K and amyloid or amyloid-like deposits.clm.	201
<input type="checkbox"/>	L9	proteinase K and amyloid or amyloid-like deposits	207
<input type="checkbox"/>	L8	L6 and prion.clm.	40
<input type="checkbox"/>	L7	L6 and prion	103
<input type="checkbox"/>	L6	proteinase K	5445
<input type="checkbox"/>	L5	L4 and L2	4
<input type="checkbox"/>	L4	amyloid fibrils	264
<input type="checkbox"/>	L3	prion and false positive.clm.	1
<input type="checkbox"/>	L2	prion and false positive	59
		<i>DB=DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L1	Hack C E.in.	9

END OF SEARCH HISTORY

## Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)  
[Generate OACS](#)

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: JP 2004091398 A

L22: Entry 1 of 4

File: DWPI

Mar 25, 2004

DERWENT-ACC-NO: 2004-262866

DERWENT-WEEK: 200425

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Proteasome activity promoting composition for use as foodstuffs, cosmetics and pharmaceuticals for removing abnormal protein and providing antiaging effect, contains kale and/or its extract

PRIORITY-DATA: 2002JP-0255449 (August 30, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>JP 2004091398 A</u>	March 25, 2004		011	A61K035/78

INT-CL (IPC): A23 L 1/30; A61 K 7/00; A61 K 7/48; A61 K 35/78; A61 P 3/10; A61 P 9/10; A61 P 9/12; A61 P 17/00; A61 P 17/16; A61 P 25/16; A61 P 25/28; A61 P 27/12; A61 P 39/02; A61 P 43/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NUMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 2. Document ID: KR 2004002906 A, WO 200283082 A2, US 20020172989 A1, US 20020192731 A1, US 6613505 B2, EP 1377677 A2, AU 2002305082 A1

L22: Entry 2 of 4

File: DWPI

Jan 7, 2004

DERWENT-ACC-NO: 2002-750710

DERWENT-WEEK: 200433

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Treatment for reducing infective prion protein at locus contaminated or suspected of being contaminated with infective prion protein by heating the locus at predetermined conditions, and exposing heated locus to proteolytic enzyme

INVENTOR: SHIH, J C H

PRIORITY-DATA: 2001US-0007613 (October 26, 2001), 2001US-0834284 (April 12, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>KR 2004002906 A</u>	January 7, 2004		000	C12Q001/37

WO 200283082 A2	October 24, 2002	E	041	A61K000/00
US 20020172989 A1	November 21, 2002		000	G01N033/53
US 20020192731 A1	December 19, 2002		000	G01N033/53
US 6613505 B2	September 2, 2003		000	C12Q001/00
EP 1377677 A2	January 7, 2004	E	000	C12Q001/00
AU 2002305082 A1	October 28, 2002		000	A61K000/00

INT-CL (IPC): A23 L 1/31; A61 K 0/00; C07 C 1/00; C07 D 201/00; C07 F 1/00; C07 H 1/00; C07 J 1/00; C07 K 1/00; C11 D 1/00; C12 N 15/09; C12 P 21/06; C12 Q 1/00; C12 Q 1/02; C12 Q 1/04; C12 Q 1/18; C12 Q 1/22; C12 Q 1/37; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/569

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

☐ 3. Document ID: DE 19822406 A1

L22: Entry 3 of 4

File: DWPI

Nov 25, 1999

DERWENT-ACC-NO: 2000-039943

DERWENT-WEEK: 200004

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Composition for treating cancer and other diseases caused by pathogenic proteins

INVENTOR: CHERKASKY, A

PRIORITY-DATA: 1998DE-1022406 (May 19, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 19822406 A1	November 25, 1999		006	A61K038/48

INT-CL (IPC): A61 K 38/48

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	---------

☐ 4. Document ID: US 5955343 A

L22: Entry 4 of 4

File: DWPI

Sep 21, 1999

DERWENT-ACC-NO: 1999-539576

DERWENT-WEEK: 200433

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Cell cultures utilizing stable macroscopic membranes formed by the self-assembly of amphiphilic peptides

INVENTOR: DIPERSIO, C M; HOLMES, T ; LOCKSHIN, C ; RICH, A ; ZHANG, S

PRIORITY-DATA: 1994US-0293284 (August 22, 1994), 1992US-0973326 (December 28, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5955343 A	September 21, 1999		049	C12N005/02

INT-CL (IPC): C12 N 5/02

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
chymotrypsin and prion	4

Display Format:

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

L7 ANSWER 16 OF 22 MEDLINE on STN  
 AN 1999022967 MEDLINE  
 DN PubMed ID: 9806020  
 TI Scrapie infectivity and **proteinase K**-resistant  
**prion** protein in sheep placenta, brain, spleen, and lymph node:  
 implications for transmission and antemortem diagnosis.  
 AU Race R; Jenny A; Sutton D  
 CS Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories,  
 National Institute of Allergy and Infectious Diseases, Hamilton, Montana,  
 59840, USA.. Rrace@atlas.niaid.nih.gov  
 SO Journal of infectious diseases, (1998 Oct) 178 (4) 949-53.  
 Journal code: 0413675. ISSN: 0022-1899.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199811  
 ED Entered STN: 19990106  
 Last Updated on STN: 19990106  
 Entered Medline: 19981120  
 AB Probable transmission of bovine spongiform encephalopathy to humans has  
 focused intense interest on all of the transmissible spongiform  
 encephalopathies (TSEs) and how they spread. In all TSEs, an abnormal  
 disease-associated, **proteinase K**-resistant protein  
 referred to as PrP-res or PrPsc accumulates in brain. In some species,  
 PrP-res accumulates in other tissues as well. Sheep placenta, brain,  
 spleen, and lymph node were analyzed in detail for PrP-res and  
 infectivity. Both were detected in all brain and spleen samples and in  
 placenta and lymph nodes of 80% of the scrapie-infected sheep. A perfect  
 correlation was observed between infectivity and PrP-res **detection**  
 . These results substantiate the probability that placenta plays an  
 important role in natural transmission of scrapie, suggest that analysis  
 of placenta for PrP-res could be the basis for an antemortem test for  
 sheep scrapie, and show that PrP-res, scrapie infectivity, and scrapie  
 disease are closely associated.  
 CT Check Tags: Female  
 Animals  
 Brain Chemistry  
 Endopeptidase K: ME, metabolism  
 Lymph Nodes: CH, chemistry

L7 ANSWER 18 OF 22 MEDLINE on STN  
AN 1998159873 MEDLINE  
DN PubMed ID: 9500237  
TI Comparison of scrapie-associated fibril **detection** and Western immunoblotting for the diagnosis of natural ovine scrapie.  
AU Cooley W A; Clark J K; Stack M J  
CS Veterinary Laboratories Agency, Central Veterinary Laboratory, Weybridge, Surrey, UK.  
SO Journal of comparative pathology, (1998 Jan) 118 (1) 41-9.  
Journal code: 0102444. ISSN: 0021-9975.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199804  
ED Entered STN: 19980507  
Last Updated on STN: 19980507  
Entered Medline: 19980427  
AB Detergent- and **proteinase K**-treated extracts of grey matter were prepared from four regions of the brains of 106 sheep with scrapie, diagnosed clinically and by the demonstration of spongiform encephalopathy. The extracts were examined by electron microscopy for the presence of scrapie-associated fibrils and by Western immunoblotting for the disease-specific abnormal **prion** protein (PrPSc). As a diagnostic method, Western immunoblotting proved to be more sensitive than electron microscopy, the **detection** rates in the 106 sheep being 97 and 91% respectively (medulla), 99 and 76% (cerebellum), 95 and 88% (frontal cerebral cortex) and 93 and 61% (occipital cerebral cortex). Neither fibrils nor PrPSc could be detected in comparable brain extracts from 25 control sheep which had shown no clinical or histopathological evidence of scrapie.  
CT Check Tags: Comparative Study; Support, Non-U.S. Gov't  
Animals  
\*Blotting, Western: VE, veterinary  
Cerebellum: CH, chemistry  
Cerebellum: UL, ultrastructure  
Microscopy, Electron

d 17 1-22 ti

- L7 ANSWER 1 OF 22 MEDLINE on STN  
TI A pitfall in diagnosis of human **prion** diseases using **detection** of protease-resistant **prion** protein in urine. Contamination with bacterial outer membrane proteins.
- L7 ANSWER 2 OF 22 MEDLINE on STN  
TI Activity of an alkaline 'cleaner' in the inactivation of the scrapie agent.
- L7 ANSWER 3 OF 22 MEDLINE on STN  
TI Discrimination between scrapie and bovine spongiform encephalopathy in sheep by molecular size, immunoreactivity, and glycoprofile of **prion** protein.
- L7 ANSWER 4 OF 22 MEDLINE on STN  
TI **Proteinase K** enhanced immunoreactivity of the **prion** protein-specific monoclonal antibody 2A11.
- L7 ANSWER 5 OF 22 MEDLINE on STN  
TI Monoclonal antibody against a peptide of human **prion** protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue.
- L7 ANSWER 6 OF 22 MEDLINE on STN  
TI Enzymatic degradation of **prion** protein in brain stem from infected cattle and sheep.
- L7 ANSWER 7 OF 22 MEDLINE on STN  
TI Improved conformation-dependent immunoassay: suitability for human **prion detection** with enhanced sensitivity.
- L7 ANSWER 8 OF 22 MEDLINE on STN  
TI Guanidine hydrochloride extraction and **detection** of **prion** proteins in mouse and hamster **prion** diseases by ELISA.
- L7 ANSWER 9 OF 22 MEDLINE on STN  
TI Concentration and removal of **prion** proteins from biological solutions.
- L7 ANSWER 10 OF 22 MEDLINE on STN  
TI A short purification process for quantitative isolation of PrPSc from naturally occurring and experimental transmissible spongiform encephalopathies.
- L7 ANSWER 11 OF 22 MEDLINE on STN  
TI Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests.
- L7 ANSWER 12 OF 22 MEDLINE on STN  
TI **Prion** protein and developments in its **detection**.
- L7 ANSWER 13 OF 22 MEDLINE on STN  
TI Early appearance but lagged accumulation of detergent-insoluble **prion** protein in the brains of mice inoculated with a mouse-adapted Creutzfeldt-Jakob disease agent.
- L7 ANSWER 14 OF 22 MEDLINE on STN  
TI Specific determination of the **proteinase K**-resistant form of the **prion** protein using two-site immunometric assays.



Application to the post-mortem diagnosis of BSE.

- L7 ANSWER 15 OF 22 MEDLINE on STN  
TI A comparative study of immunohistochemical methods for detecting abnormal **prion** protein with monoclonal and polyclonal antibodies.
- L7 ANSWER 16 OF 22 MEDLINE on STN  
TI Scrapie infectivity and **proteinase K**-resistant **prion** protein in sheep placenta, brain, spleen, and lymph node: implications for transmission and antemortem diagnosis.
- L7 ANSWER 17 OF 22 MEDLINE on STN  
TI **Detection** and discrimination of PrPSc by multi-spectral ultraviolet fluorescence.
- L7 ANSWER 18 OF 22 MEDLINE on STN  
TI Comparison of scrapie-associated fibril **detection** and Western immunoblotting for the diagnosis of natural ovine scrapie.
- L7 ANSWER 19 OF 22 MEDLINE on STN  
TI The protein product of the het-s heterokaryon incompatibility gene of the fungus *Podospora anserina* behaves as a **prion** analog.
- L7 ANSWER 20 OF 22 MEDLINE on STN  
TI Capillary electrophoresis of the scrapie **prion** protein from sheep brain.
- L7 ANSWER 21 OF 22 MEDLINE on STN  
TI **Detection** of **proteinase K**-resistant **prion** protein and infectivity in mouse spleen by 2 weeks after scrapie agent inoculation.
- L7 ANSWER 22 OF 22 MEDLINE on STN  
TI Scrapie-infected murine neuroblastoma cells produce protease-resistant **prion** proteins.



d his

(FILE 'HOME' ENTERED AT 16:30:54 ON 21 JUN 2004)

FILE 'MEDLINE' ENTERED AT 16:31:04 ON 21 JUN 2004

L1	205 S	PROTEINASE K AND PRION
L2	1 S	CASEIN RESORUFIN
L3	14872 S	CASEIN
L4	0 S	L1 AND L3
L5	52 S	CASEIN SUBSTRATE
L6	0 S	L1 AND L5
L7	22 S	DETECTION AND L1
L8	4 S	CHYMOTRYPSIN AND PRION
L9	0 S	SAAPPN

effect (all claimed) caused by stress, ultraviolet radiation and oxidation. Also for preventing other lifestyle related diseases such as neurodegenerative disease, Alzheimer's disease, Parkinson's disease, hypertension, diabetes, arteriosclerosis, polyglutamin disease, prion disease, amyotrophic lateral sclerosis, wrinkles, etc.

ADVANTAGE - The composition is safe for use and has excellent stability. Inexpensive foodstuffs, cosmetics and pharmaceuticals are provided using the composition.

DESCRIPTION OF DRAWING(S) - The graph shows proteasome activity in rat hepatocytes, processed with kale extract. (Drawing includes non-English language text).

ABSTRACTED-PUB-NO: JP2004091398A  
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.1/2

First Hit☐ [Generate Collection](#) [Print](#)

L22: Entry 1 of 4

File: DWPI

Mar 25, 2004

DERWENT-ACC-NO: 2004-262866

DERWENT-WEEK: 200425

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Proteasome activity promoting composition for use as foodstuffs, cosmetics and pharmaceuticals for removing abnormal protein and providing antiaging effect, contains kale and/or its extract

PRIORITY-DATA: 2002JP-0255449 (August 30, 2002)

[Search Selected](#)[Search ALL](#)[Clear](#)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <a href="#">JP 2004091398 A</a>	March 25, 2004		011	A61K035/78

INT-CL (IPC): [A23 L 1/30](#); [A61 K 7/00](#); [A61 K 7/48](#); [A61 K 35/78](#); [A61 P 3/10](#); [A61 P 9/10](#); [A61 P 9/12](#); [A61 P 17/00](#); [A61 P 17/16](#); [A61 P 25/16](#); [A61 P 25/28](#); [A61 P 27/12](#); [A61 P 39/02](#); [A61 P 43/00](#)

ABSTRACTED-PUB-NO: JP2004091398A

## BASIC-ABSTRACT:

NOVELTY - Proteasome activity promoting composition contains kale and/or its extract.

ACTIVITY - Dermatological; Neuroprotective; Nootropic; Antiparkinsonian; Hypotensive; Antidiabetic; Antiarteriosclerotic; Antimicrobial-Gen. Aging suppressing effect of kale extract was evaluated by measuring carbonylation protein in liver extract derived from rat, in which oxidative stress was induced by Nakamura et al., Journal of biochemistry, volume 199, page 768-774, 1996. The experiment was performed in 4 week old Wister male rat. Kale extract was administered at a dose of 250 mg/kg. Liver was extracted and amount of carbonylation protein present was measured. Anti-2,4-dinitrophenyl hydrazine labeled antibody, which specifically coupled with carbonyl group of protein carbonylated by oxidation trauma was used, and carbonylation protein was detected. The group administered with kale extract effectively reduced production of carbonylation protein and exhibited excellent aging inhibitory effect.

MECHANISM OF ACTION - Proteasome-Stimulator. Proteasome activity enhancing effect of kale extract was evaluated in rat hepatocytes (clone 9). 0.1, 1, 10 and 100 µg/ml of the kale leaf extract was added to the cell culture. Trypsin-t-butyloxy carbonyl-L-leucyl-L-arginyl-L-arginyl-4-methy-1-coumaryl-7-amide was used as substrate for measuring chymotrypsin-like proteasome activity. The result showed that the kale extract had excellent proteasome stimulating activity.

USE - As foodstuffs, cosmetics and pharmaceuticals for removing abnormal protein, preventing and treating disease caused by abnormal protein and providing antiaging

L7 ANSWER 14 OF 22 MEDLINE on STN  
 AN 2001180428 MEDLINE  
 DN PubMed ID: 11214923  
 TI Specific determination of the **proteinase K**-resistant form of the **prion** protein using two-site immunometric assays. Application to the post-mortem diagnosis of BSE.  
 AU Grassi J; Creminon C; Frobert Y; Fretier P; Turbica I; Rezaei H; Hunsmann G; Comoy E; Deslys J P  
 CS CEA, Service de Pharmacologie et d'Immunologie, CEA Saclay, Gif sur Yvette, France.  
 SO Archives of virology. Supplementum, (2000) (16) 197-205. Journal code: 9214275. ISSN: 0939-1983.  
 CY Austria  
 DT (EVALUATION STUDIES)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200103  
 ED Entered STN: 20010404  
 Last Updated on STN: 20010404  
 Entered Medline: 20010329  
 AB The aim of this work was to establish an immunological test suitable for specifically detecting PrPres in tissues from animals or humans developing TSEs. We chose to use as **detection** method a conventional two-site immunometric assay (sandwich immunoassay) because over the last 20 years this technique has clearly been shown to be more sensitive and specific than other tests. We have established numerous two-site immunometric assays based on the use of monoclonal antibodies and suitable for measurement of PrPsen in various mammalian species (human, bovine, ovine, mouse and hamster). A **detection** limit below 100 pg/ml was estimated from standard curves established using ovine recombinant PrP. PrPres was selectively detected by processing samples (currently brain homogenates) to enable specific purification and concentration of PrPres, which was finally solubilized by a strong denaturing treatment. This sample-processing procedure can be achieved within 30 minutes. The capacity of this test to detect bovine PrPres was estimated in the framework of an evaluation study organized by the Directorate-General XXIV of the European Commission during May 1999. On this occasion, a blind test on 1400 brain stem samples taken from either healthy (1000) or BSE-infected (300) cows demonstrated 100% sensitivity and specificity. In addition, dilution experiments showed that the test can significantly detect PrPres in homogenates diluted 1/300 and was at least as sensitive as a conventional bioassay performed on mice.  
 CT Animals  
 Autopsy  
 \*Brain Stem: CH, chemistry  
 Cattle  
 \*Encephalopathy, Bovine Spongiform: DI, diagnosis  
 Encephalopathy, Bovine Spongiform: ET, etiology